BiotechTube

AZD4144 + Placebo

Phase 2Recruiting
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Sepsis

Conditions

Sepsis, Acute Kidney Injury

Trial Timeline

Feb 10, 2026 → Feb 11, 2027

NCT ID
NCT07215702

About AZD4144 + Placebo

AZD4144 + Placebo is a phase 2 stage product being developed by AstraZeneca for Sepsis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07215702. Target conditions include Sepsis, Acute Kidney Injury.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT07215702Phase 2Recruiting
NCT06942923Phase 1Completed

Competing Products

20 competing products in Sepsis

See all competitors
ProductCompanyStageHype Score
Alkaline Phosphatase + PlaceboAM-PharmaPhase 2
44
Drotrecogin alfa (activated)Eli LillyPhase 2
52
MeropenemPfizerApproved
84
ImipenemMerckApproved
85
CefiderocolShionogiPhase 1
33
eritoran tetrasodium + PlaceboEisaiPhase 3
77
E5564EisaiPhase 2
52
Drotrecogin Alfa (Activated) + placeboEli LillyPhase 3
77
Drotrecogin alfa (activated) + PlaceboEli LillyPhase 3
77
Drotrecogin Alfa (activated)Eli LillyApproved
85
Drotrecogin alfa (activated) + PlaceboEli LillyPhase 3
77
Drotrecogin alfa (activated) + PlaceboEli LillyPhase 3
77
sPLA2 InhibitorEli LillyPhase 1/2
41
Drotrecogin alfa (activated)Eli LillyApproved
85
Drotrecogin Alfa (Activated) + Unfractionated heparin + Low molecular weight heparinEli LillyApproved
85
drotrecogin alfa (activated)Eli LillyApproved
85
drotrecogin alfa (activated)Eli LillyApproved
85
AZD9773 (CytoFab)AstraZenecaPhase 2
52
AZD9773 + PlaceboAstraZenecaPhase 2
52
AZD9773 + PlaceboAstraZenecaPhase 2
52

Other Products from AstraZeneca

QuetiapineApproved
85
Dapagliflozin 5 mg + Placebo tabletApproved
85
QuetiapineApproved
85
Ticagrelor + ClopidogrelApproved
85
DurvalumabApproved
85